Since GSK had joined a deal with Roche that has held for over ten years, in which GSK would dominate vaccines and Roche would dominate antivirals (a mammoth effort by GSK since Tamiflu turned out to be so much weaker than Relenza) then I predict that Roche will get LANI, over GSK. Or someone else who wasn't part of the secret pharmaceutical mens club will get LANI.
What a pity Biota management are content to give inventions away, rather than build a factory (like D.Sankyo did)and sell our own product.
Obviously too much visible wealth would make the natives restless i.e. the tribes of hard working but simple Biota shareholders might revolt at too much profit displayed by the Biota management masters, while no dividend for the shareholders is ever planned.
- Forums
- ASX - By Stock
- BTA
- tamiflu end of shelf life roche gilead
tamiflu end of shelf life roche gilead, page-3
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online